Literature DB >> 24127173

Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice.

Vagelis Rinotas1, Alexandra Niti, Romain Dacquin, Nicolas Bonnet, Marina Stolina, Chun-Ya Han, Paul Kostenuik, Pierre Jurdic, Serge Ferrari, Eleni Douni.   

Abstract

Receptor activator of NF-κB ligand (RANKL) plays a key role in osteoclast-induced bone resorption across a range of degenerative bone diseases, and its specific inhibition has been recently approved as a treatment for women with postmenopausal osteoporosis at high or increased risk of fracture in the United States and globally. In the present study, we generated transgenic mice (TghuRANKL) carrying the human RANKL (huRANKL) genomic region and achieved a physiologically relevant pattern of RANKL overexpression in order to establish novel genetic models for assessing skeletal and extraskeletal pathologies associated with excessive RANKL and for testing clinical therapeutic candidates that inhibit human RANKL. TghuRANKL mice of both sexes developed early-onset bone loss, and the levels of huRANKL expression were correlated with bone resorption and disease severity. Low copy Tg5516 mice expressing huRANKL at low levels displayed a mild osteoporotic phenotype as shown by trabecular bone loss and reduced biomechanical properties. Notably, overexpression of huRANKL, in the medium copy Tg5519 line, resulted in severe early-onset osteoporosis characterized by lack of trabecular bone, destruction of the growth plate, increased osteoclastogenesis, bone marrow adiposity, increased bone remodeling, and severe cortical bone porosity accompanied by decreased bone strength. An even more severe skeletal phenotype developed in the high copy Tg5520 founder with extensive soft tissue calcification. Model validation was further established by evidence that denosumab, an antibody that inhibits human but not murine RANKL, fully corrected the hyper-resorptive and osteoporotic phenotypes of Tg5519 mice. Furthermore, overexpression of huRANKL rescued osteopetrotic phenotypes of RANKL-defective mice. These novel huRANKL transgenic models of osteoporosis represent an important advance for understanding the pathogenesis and treatment of high-turnover bone diseases and other disease states caused by excessive RANKL.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  ANIMAL MODELS; BONE; OSTEOPOROSIS; RANKL; TREATMENT

Mesh:

Substances:

Year:  2014        PMID: 24127173     DOI: 10.1002/jbmr.2112

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  23 in total

Review 1.  Molecular Mechanisms of Vascular Calcification in Chronic Kidney Disease: The Link between Bone and the Vasculature.

Authors:  Chang Hyun Byon; Yabing Chen
Journal:  Curr Osteoporos Rep       Date:  2015-08       Impact factor: 5.096

2.  RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass.

Authors:  Nicolas Bonnet; Lucie Bourgoin; Emmanuel Biver; Eleni Douni; Serge Ferrari
Journal:  J Clin Invest       Date:  2019-05-23       Impact factor: 14.808

3.  A DNA segment spanning the mouse Tnfsf11 transcription unit and its upstream regulatory domain rescues the pleiotropic biologic phenotype of the RANKL null mouse.

Authors:  Melda Onal; Kathleen A Bishop; Hillary C St John; Allison L Danielson; Erin M Riley; Marilina Piemontese; Jinhu Xiong; Joseph J Goellner; Charles A O'Brien; J Wesley Pike
Journal:  J Bone Miner Res       Date:  2015-05       Impact factor: 6.741

4.  RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non-Metastatic Ovarian Cancer in Mice.

Authors:  Fabrizio Pin; Alexander J Jones; Joshua R Huot; Ashok Narasimhan; Teresa A Zimmers; Lynda F Bonewald; Andrea Bonetto
Journal:  J Bone Miner Res       Date:  2021-12-13       Impact factor: 6.390

5.  Transgenic Mice Carrying GLUD2 as a Tool for Studying the Expressional and the Functional Adaptation of this Positive Selected Gene in Human Brain Evolution.

Authors:  Andreas Plaitakis; Dimitra Kotzamani; Zoe Petraki; Maria Delidaki; Vagelis Rinotas; Ioannis Zaganas; Eleni Douni; Kyriaki Sidiropoulou; Cleanthe Spanaki
Journal:  Neurochem Res       Date:  2018-05-18       Impact factor: 3.996

6.  Immuno-PET Molecular Imaging of RANKL in Cancer.

Authors:  Jonatan Dewulf; Christel Vangestel; Yannick Verhoeven; Jorrit De Waele; Karen Zwaenepoel; Peter A van Dam; Filipe Elvas; Tim Van den Wyngaert
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

7.  The mammalian lectin galectin-8 induces RANKL expression, osteoclastogenesis, and bone mass reduction in mice.

Authors:  Yaron Vinik; Hadas Shatz-Azoulay; Alessia Vivanti; Navit Hever; Yifat Levy; Rotem Karmona; Vlad Brumfeld; Saja Baraghithy; Malka Attar-Lamdar; Sigalit Boura-Halfon; Itai Bab; Yehiel Zick
Journal:  Elife       Date:  2015-05-08       Impact factor: 8.140

8.  A splicing mutation in the novel mitochondrial protein DNAJC11 causes motor neuron pathology associated with cristae disorganization, and lymphoid abnormalities in mice.

Authors:  Fotis Ioakeimidis; Christine Ott; Vera Kozjak-Pavlovic; Foteini Violitzi; Vagelis Rinotas; Eleni Makrinou; Elias Eliopoulos; Costas Fasseas; George Kollias; Eleni Douni
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

9.  Transcriptional regulation of the human TNFSF11 gene in T cells via a cell type-selective set of distal enhancers.

Authors:  Kathleen A Bishop; Xiaohua Wang; Heidi M Coy; Mark B Meyer; Jenny E Gumperz; J Wesley Pike
Journal:  J Cell Biochem       Date:  2015-02       Impact factor: 4.480

10.  Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study.

Authors:  Yukio Nakamura; Mikio Kamimura; Shota Ikegami; Keijiro Mukaiyama; Shigeharu Uchiyama; Akira Taguchi; Hiroyuki Kato
Journal:  BMC Endocr Disord       Date:  2015-12-15       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.